PharmaTher Holdings Ltd (PHRM) AI Stock Analysis

• Market Cap: $19.47M
• Dividend Yield: N/A
• Average Volume (3M): 36.75K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.10
• Revenue Growth: N/A
• EPS Growth: 66.13%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 88,519,066
• 10 Day Avg. Volume: 33,707
• 30 Day Avg. Volume: 36,747
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

PharmaTher Holdings Ltd. faces substantial financial hurdles, with no revenue and persistent losses weighing heavily on its stock score. However, recent positive corporate developments regarding FDA approval for ketamine could provide a significant future boost. Technical indicators are currently neutral, and valuation metrics reflect typical challenges for biotech firms in early stages. The potential regulatory approval is a key factor for future growth, but immediate financial struggles limit the current score.

PharmaTher Holdings Ltd Business Overview & Revenue Model

Company Description

PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.

How the Company Makes Money

PharmaTher Holdings Ltd generates revenue primarily through the development and commercialization of its proprietary psychedelic-based therapies. The company's revenue model includes licensing agreements, partnerships, and collaborative research and development efforts with other pharmaceutical companies. These agreements often involve upfront payments, milestone payments, and royalties on sales of successful therapies. Additionally, PharmaTher may receive funding from grants and government programs that support research in psychedelic medicine. The company's focus on strategic collaborations and intellectual property development plays a critical role in its ability to generate revenue and sustain growth in the competitive biotech landscape.

PharmaTher Holdings Ltd Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-711.00	-1.42K	-1.78K	-355.00	0.00
	EBIT
-3.04M	―	―	-8.52M	-23.82K
	EBITDA
-3.04M	-3.96M	-3.96M	-2.43M	0.00
	Net Income Common Stockholders
-3.12M	-6.42M	-4.01M	2.66M	-23.82K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.30M	6.25M	12.12M	5.88M	388.38K
	Total Assets
2.59M	6.31M	12.16M	5.94M	390.43K
	Total Debt
0.00	0.00	0.00	0.00	0.00
	Net Debt
-2.13M	-5.92M	-9.15M	-2.78M	-388.38K
	Total Liabilities
252.90K	892.48K	330.32K	361.06K	10.75K
	Stockholders Equity
2.34M	5.42M	11.83M	5.58M	379.69K
Cash Flow		Free Cash Flow
-3.52M	-3.24M	-3.51M	917.92K	―
	Operating Cash Flow
-3.52M	-3.24M	-3.51M	922.19K	―
	Investing Cash Flow
-300.00K	0.00	0.00	214.77K	0.00
	Financing Cash Flow
35.00K	0.00	9.89M	1.25M	388.50K

PharmaTher Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PHRM, the sentiment is Positive. The current price of 0.21 is above the 20-day moving average (MA) of 0.20, above the 50-day MA of 0.20, and below the 200-day MA of 0.22, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.65 is Neutral, neither overbought nor oversold. The STOCH value of 87.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:PHRM.

PharmaTher Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.23B	3.70	-41.86%	2.84%	16.58%	-0.16%
PHRM	44 Neutral	$19.47M	―	-76.00%	―	―	66.13%

PharmaTher Holdings Ltd Corporate Events

PharmaTher Receives FDA Approval Goal Date for Ketamine

PharmaTher Holdings Ltd. announced that it has received an Amendment Acknowledgement Letter from the U.S. FDA for its New Drug Application for Ketamine, with an approval goal date set for June 4, 2025. This development positions PharmaTher to potentially become a leading supplier of Ketamine in the U.S., addressing the ongoing shortage and filling the demand gap. The company has addressed minor deficiencies noted by the FDA and aims to remove Ketamine from the FDA’s drug shortage list, which would restrict compound pharmacies from supplying it, thereby strengthening PharmaTher’s market position.

PharmaTher Resubmits FDA Application for Ketamine, Aiming for Q2-2025 Approval

PharmaTher Holdings Ltd. has resubmitted its application to the FDA for the approval of Ketamine, addressing minor deficiencies previously noted by the agency. The company anticipates FDA approval in the second quarter of 2025, which could significantly impact the Ketamine shortage in the U.S. and enhance its use in treating various medical conditions. This move positions PharmaTher as a key player in addressing the Ketamine shortage and unlocking its potential for broader medical applications.

PharmaTher Advances Towards FDA Approval for Ketamine with Resubmission Plan

PharmaTher Holdings Ltd. announced that it is on track to resubmit information to the FDA by the end of February 2025, following a complete response letter that identified minor deficiencies. The company anticipates that this minor amendment will lead to a new FDA approval date in the second quarter of 2025 for ketamine, which is essential for anesthesia and pain relief, and is also used for mental health and neurological disorders. The successful approval could significantly strengthen PharmaTher’s market position as a key innovator in ketamine-based treatments, potentially impacting millions of patients worldwide.